Bevacizumab for Advanced Breast Cancer: All Tied Up With a RIBBON?

被引：38

作者：

Burstein, Harold J. ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 10期

关键词：

1ST-LINE TREATMENT; PHASE-III; PACLITAXEL;

D O I：

10.1200/JCO.2010.33.2684

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1232 / 1235

页数：5

共 15 条

[1] Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer [J].

Burzykowski, Tomasz ;

Buyse, Marc ;

Piccart-Gebhart, Martine J. ;

Sledge, George ;

Carmichael, James ;

Lueck, Hans-Joachim ;

Mackey, John R. ;

Nabholtz, Jean-Marc ;

Paridaens, Robert ;

Biganzoli, Laura ;

Jassem, Jacek ;

Bontenbal, Marijke ;

Bonneterre, Jacques ;

Chan, Stephen ;

Basaran, Gul Atalay ;

Therasse, Patrick .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) :1987-1992

[2]

Choueiri TK., 2015, J Clin Oncol

[3] Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation [J].

Dedes, Konstantin J. ;

Matter-Walstra, Klazien ;

Schwenkglenks, Matthias ;

Pestalozzi, Bernhard C. ;

Fink, Daniel ;

Brauchli, Peter ;

Szucs, Thomas D. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (08) :1397-1406

[4]

*EUR MED AG, 2010, QUEST ANSW REV AV BE

[5] Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer [J].

Gray, Robert ;

Bhattacharya, Suman ;

Bowden, Christopher ;

Miller, Kathy ;

Comis, Robert L. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) :4966-4972

[6]

Kolata Gina, 2008, NY TIMES 0706

[7] SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer [J].

Mayer, E. L. ;

Dhakil, S. ;

Patel, T. ;

Sundaram, S. ;

Fabian, C. ;

Kozloff, M. ;

Qamar, R. ;

Volterra, F. ;

Parmar, H. ;

Samant, M. ;

Burstein, H. J. .

ANNALS OF ONCOLOGY, 2010, 21 (12) :2370-2376

[8] Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer [J].

Miles, David W. ;

Chan, Arlene ;

Dirix, Luc Y. ;

Cortes, Javier ;

Pivot, Xavier ;

Tomczak, Piotr ;

Delozier, Thierry ;

Sohn, Joo Hyuk ;

Provencher, Louise ;

Puglisi, Fabio ;

Harbeck, Nadia ;

Steger, Guenther G. ;

Schneeweiss, Andreas ;

Wardley, Andrew M. ;

Chlistalla, Andreas ;

Romieu, Gilles .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3239-3247

[9] Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer [J].

Miller, Kathy ;

Wang, Molin ;

Gralow, Julie ;

Dickler, Maura ;

Cobleigh, Melody ;

Perez, Edith A. ;

Shenkier, Tamara ;

Cella, David ;

Davidson, Nancy E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (26) :2666-2676

[10] Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer [J].

Miller, KD ;

Chap, LI ;

Holmes, FA ;

Cobleigh, MA ;

Marcom, PK ;

Fehrenbacher, L ;

Dickler, M ;

Overmoyer, BA ;

Reimann, JD ;

Sing, AP ;

Langmuir, V ;

Rugo, HS .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :792-799

← 1 2 →